Gastrointestinal stromal tumor: Current approaches and future directions in the treatment of advanced disease
Last Updated: Wednesday, May 21, 2025
The article reviews treatment for advanced gastrointestinal stromal tumors, covering current tyrosine kinase inhibitors (imatinib, sunitinib, regorafenib, ripretinib, avapritinib). It emphasizes individualized, mutation-guided strategies by multidisciplinary expert teams, and explores future next-generation inhibitors and combination therapies.
Advertisement
News & Literature Highlights